199 related articles for article (PubMed ID: 22873221)
1. Angiogenesis in hepatocellular carcinoma: a potential target for chemoprevention and therapy.
Bishayee A; Darvesh AS
Curr Cancer Drug Targets; 2012 Nov; 12(9):1095-118. PubMed ID: 22873221
[TBL] [Abstract][Full Text] [Related]
2. Vascular changes in hepatocellular carcinoma.
Yang ZF; Poon RT
Anat Rec (Hoboken); 2008 Jun; 291(6):721-34. PubMed ID: 18484619
[TBL] [Abstract][Full Text] [Related]
3. Dietary phytochemicals in the chemoprevention and treatment of hepatocellular carcinoma: in vivo evidence, molecular targets, and clinical relevance.
Bishayee A; Thoppil RJ; Waghray A; Kruse JA; Novotny NA; Darvesh AS
Curr Cancer Drug Targets; 2012 Nov; 12(9):1191-232. PubMed ID: 22873222
[TBL] [Abstract][Full Text] [Related]
4. Hypoxia and hepatocellular carcinoma: The therapeutic target for hepatocellular carcinoma.
Wu XZ; Xie GR; Chen D
J Gastroenterol Hepatol; 2007 Aug; 22(8):1178-82. PubMed ID: 17559361
[TBL] [Abstract][Full Text] [Related]
5. Angiogenesis and antiangiogenic therapy in hepatocellular carcinoma.
Pang R; Poon RT
Cancer Lett; 2006 Oct; 242(2):151-67. PubMed ID: 16564617
[TBL] [Abstract][Full Text] [Related]
6. Angiogenesis and anti-angiogenesis in hepatocellular carcinoma.
Ribatti D; Vacca A; Nico B; Sansonno D; Dammacco F
Cancer Treat Rev; 2006 Oct; 32(6):437-44. PubMed ID: 16870349
[TBL] [Abstract][Full Text] [Related]
7. Molecular targeted therapies in hepatocellular carcinoma.
Tanaka S; Arii S
Semin Oncol; 2012 Aug; 39(4):486-92. PubMed ID: 22846865
[TBL] [Abstract][Full Text] [Related]
8. Antiangiogenic strategies in hepatocellular carcinoma: current status.
Zacharoulis D; Hatzitheofilou C; Athanasiou E; Zacharoulis S
Expert Rev Anticancer Ther; 2005 Aug; 5(4):645-56. PubMed ID: 16111465
[TBL] [Abstract][Full Text] [Related]
9. Current status and perspective of antiangiogenic therapy for cancer: hepatocellular carcinoma.
Tanaka S; Arii S
Int J Clin Oncol; 2006 Apr; 11(2):82-9. PubMed ID: 16622743
[TBL] [Abstract][Full Text] [Related]
10. Angiogenic activity of hepatitis B and C viruses.
Vrancken K; Paeshuyse J; Liekens S
Antivir Chem Chemother; 2012 Jan; 22(4):159-70. PubMed ID: 22182803
[TBL] [Abstract][Full Text] [Related]
11. Resveratrol in the chemoprevention and treatment of hepatocellular carcinoma.
Bishayee A; Politis T; Darvesh AS
Cancer Treat Rev; 2010 Feb; 36(1):43-53. PubMed ID: 19910122
[TBL] [Abstract][Full Text] [Related]
12. From molecular biology to targeted therapies for hepatocellular carcinoma: the future is now.
Pang RW; Poon RT
Oncology; 2007; 72 Suppl 1():30-44. PubMed ID: 18087180
[TBL] [Abstract][Full Text] [Related]
13. Targeting vessels to treat hepatocellular carcinoma.
Romanque P; Piguet AC; Dufour JF
Clin Sci (Lond); 2008 Apr; 114(7):467-77. PubMed ID: 18302534
[TBL] [Abstract][Full Text] [Related]
14. Clinical significance of microvessel density and vascular endothelial growth factor expression in hepatocellular carcinoma and surrounding liver: possible involvement of vascular endothelial growth factor in the angiogenesis of cirrhotic liver.
El-Assal ON; Yamanoi A; Soda Y; Yamaguchi M; Igarashi M; Yamamoto A; Nabika T; Nagasue N
Hepatology; 1998 Jun; 27(6):1554-62. PubMed ID: 9620326
[TBL] [Abstract][Full Text] [Related]
15. Adeno-associated virus-mediated expression of apolipoprotein (a) kringles suppresses hepatocellular carcinoma growth in mice.
Lee K; Yun ST; Kim YG; Yoon Y; Jo EC
Hepatology; 2006 May; 43(5):1063-73. PubMed ID: 16628632
[TBL] [Abstract][Full Text] [Related]
16. Synergistic inhibition of hepatocellular carcinoma growth and hepatocarcinogenesis by combination of 5-fluorouracil and angiotensin-converting enzyme inhibitor via anti-angiogenic activities.
Yanase K; Yoshiji H; Ikenaka Y; Noguchi R; Kitade M; Kaji K; Yoshii J; Namisaki T; Yamazaki M; Asada K; Tsujimoto T; Akahane T; Uemura M; Fukui H
Oncol Rep; 2007 Feb; 17(2):441-6. PubMed ID: 17203185
[TBL] [Abstract][Full Text] [Related]
17. Anti-angiogenic therapy for HCC.
Dufour JF
Minerva Gastroenterol Dietol; 2012 Mar; 58(1):81-6. PubMed ID: 22419006
[TBL] [Abstract][Full Text] [Related]
18. Tum-1, a tumstatin fragment, gene delivery into hepatocellular carcinoma suppresses tumor growth through inhibiting angiogenesis.
Goto T; Ishikawa H; Matsumoto K; Nishimura D; Kusaba M; Taura N; Shibata H; Miyaaki H; Ichikawa T; Hamasaki K; Nakao K; Maeshima Y; Eguchi K
Int J Oncol; 2008 Jul; 33(1):33-40. PubMed ID: 18575748
[TBL] [Abstract][Full Text] [Related]
19. The angiogenic makeup of human hepatocellular carcinoma does not favor vascular endothelial growth factor/angiopoietin-driven sprouting neovascularization.
Zeng W; Gouw AS; van den Heuvel MC; Zwiers PJ; Zondervan PE; Poppema S; Zhang N; Platteel I; de Jong KP; Molema G
Hepatology; 2008 Nov; 48(5):1517-27. PubMed ID: 18924243
[TBL] [Abstract][Full Text] [Related]
20. New strategy of antiangiogenic therapy for hepatocellular carcinoma.
Wu XZ
Neoplasma; 2008; 55(6):472-81. PubMed ID: 18999874
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
